Who are the top shareholders of the Indoco Remedies?

The top shareholders of Indoco Remedies include Spa Holdings Pvt Ltd with 19.88%, mutual funds holding 18.52%, and individual investors owning 15.99%. Notably, Nippon Life India Trustee Ltd is the largest public shareholder with 4.8%.

The top shareholders of Indoco Remedies include a mix of promoters and institutional investors. The largest promoter is Spa Holdings Pvt Ltd, which holds 19.88% of the shares. The promoters collectively hold a significant portion of the company, with no pledged promoter holdings reported. <BR><BR>In terms of institutional investors, mutual funds hold 18.52% of the shares through 8 different schemes, while foreign institutional investors (FIIs) have a smaller stake of 1.24% across 39 entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund and holds 4.8%. Additionally, individual investors collectively own 15.99% of the company.

What does Indoco Remedies do?

Indoco Remedies Ltd is a Mumbai-based pharmaceutical company focused on formulations, with a market cap of Rs 2,532 Cr. As of March 2025, it reported net sales of 341 Cr and a net loss of 26 Cr.

Overview: <BR>Indoco Remedies Ltd is a Mumbai-based pharmaceutical company focused on formulations, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History: <BR>Indoco Remedies Limited was incorporated on August 23, 1947. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 341 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 2,532 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.54% <BR>Debt-Equity: 0.96 <BR>Return on Equity: -7.31% <BR>Price to Book: 2.53<BR><BR>Contact Details: <BR>Address: Indoco House 166 C S T Road, Santacruz (East) Kalina Mumbai Maharashtra : 400098 <BR>Tel: 91-022-26541851-55 <BR>Email: jagdishs@indoco.com <BR>Website: http://www.indoco.com

What is the bonus history of the Indoco Remedies?

Indoco Remedies issued a bonus share in a 1:2 ratio on May 17, 2012, with a record date of May 19, 2012. This is the most recent bonus action recorded for the company.

Indoco Remedies has a bonus history that includes a notable issue announced on May 17, 2012. The company issued a bonus in the ratio of 1:2, meaning that for every two shares held, shareholders received one additional share. The record date for this bonus was May 19, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Indoco Remedies or need further details, feel free to ask!

Has Indoco Remedies declared dividend?

Indoco Remedies Ltd has declared a 75% dividend, amounting to ₹1.5 per share, with an ex-date of September 19, 2024. Despite the dividend, the company's stock has experienced significant price declines over various periods, resulting in negative total returns in the short term.

Indoco Remedies Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.54%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.9%, with a dividend return of 0%, resulting in a total return of -14.9%.<BR><BR>Over the past year, the price return was -12.95%, the dividend return was 0.46%, leading to a total return of -12.49%.<BR><BR>In the 2-year period, the price return was -16.99%, the dividend return was 1.13%, culminating in a total return of -15.86%.<BR><BR>For the 3-year period, the price return was -27.73%, with a dividend return of 1.43%, resulting in a total return of -26.3%.<BR><BR>In the last 4 years, the price return was -29.74%, the dividend return was 1.73%, which led to a total return of -28.01%.<BR><BR>Over the 5-year period, the price return was 22.57%, with a dividend return of 3.36%, resulting in a total return of 25.93%.<BR><BR>Overall, while Indoco Remedies has declared a dividend, the total returns over various periods indicate significant price declines, particularly in the shorter terms, suggesting challenges in the company's stock performance despite the dividend declaration.

Who are the peers of the Indoco Remedies?

Indoco Remedies' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Amrutanjan Health, Syncom Formulations, Windlas Biotech, Sigachi Industries, and Beta Drugs Ltd. Indoco Remedies has average management risk and capital structure, with a 1-year return of -10.95%, outperforming only Sigachi Industries.

Peers: The peers of Indoco Remedies are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Amrutanjan Healt, Syncom Formul., Windlas Biotech, Sigachi Indust., and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Amrutanjan Healt, while Average management risk is found at Indoco Remedies, Syncom Formul., Windlas Biotech, Sigachi Indust., and Beta Drugs Ltd. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted for Divi's Lab., Torrent Pharma, Indoco Remedies, Amrutanjan Healt, Syncom Formul., Windlas Biotech, Sigachi Indust., and Beta Drugs Ltd. Excellent capital structure is seen in Sun Pharma.Inds., Divi's Lab., Cipla, and Amrutanjan Healt, while average capital structure is found at Indoco Remedies, and good capital structure is noted for Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Sigachi Indust. at -17.67%. Indoco Remedies has a 1-year return of -10.95%, which is higher than Sigachi Indust. but lower than all other peers. Additionally, the six-month return is negative for Indoco Remedies, Sun Pharma.Inds., Torrent Pharma, and Windlas Biotech.

Is Indoco Remedies overvalued or undervalued?

As of May 23, 2025, Indoco Remedies is considered overvalued and risky due to troubling financial ratios, including a PE ratio of -33.83 and negative returns year-to-date, especially when compared to more profitable peers like Sun Pharma and Cipla.

As of 23 May 2025, the valuation grade for Indoco Remedies has moved from attractive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE ratio of -33.83, an EV to EBIT ratio of -240.53, and a ROE of -7.31%. These figures suggest that the company is struggling to generate profits and is not performing well compared to its peers.<BR><BR>In comparison to industry peers, Indoco Remedies stands out unfavorably; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights the challenges Indoco Remedies faces in the current market environment. Additionally, while the stock has recently outperformed the Sensex over the past week and month, its year-to-date and one-year returns remain negative, further reinforcing the notion that the stock is overvalued in light of its financial performance.

When is the next results date for Indoco Remedies?

Indoco Remedies will announce its results on 24 July 2025.

Indoco Remedies will declare its results on 24 July 2025.

Who are in the management team of Indoco Remedies?

As of March 2023, the management team of Indoco Remedies includes Suresh G Kare (Chairman & Wholetime Director), Aditi Kare Panandikar (Managing Director), Sundeep V Bambolkar (Joint Managing Director), and several independent and non-executive directors. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Indoco Remedies includes the following individuals:<BR><BR>1. Suresh G Kare - Chairman & Wholetime Director<BR>2. Aditi Kare Panandikar - Managing Director<BR>3. Sundeep V Bambolkar - Joint Managing Director<BR>4. Rajiv Kakodkar - Independent Non-Executive Director<BR>5. D M Gavaskar - Independent Non-Executive Director<BR>6. Vasudha V Kamat - Independent Non-Executive Director<BR>7. Abhijit Y Gore - Independent Non-Executive Director<BR>8. Anand Nadkarni - Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

How big is Indoco Remedies?

As of 24th July, Indoco Remedies Ltd has a market capitalization of 2,907.00 Cr, with recent net sales of 1,671.31 Cr and a net profit loss of 112.14 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Indoco Remedies Ltd has a market capitalization of 2,907.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,671.31 Cr, while the sum of Net Profit for the same period shows a loss of 112.14 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds stand at 1,109.90 Cr, and Total Assets are valued at 2,144.73 Cr.

Are Indoco Remedies latest results good or bad?

Indoco Remedies' latest results show mixed performance, with a significant reduction in net loss and revenue growth, but persistent losses and declining operating margins raise concerns about its financial health and operational efficiency.

Indoco Remedies' latest results present a mixed picture. On one hand, the company reported a sequential improvement in its bottom-line performance, with a net loss of ₹7.93 crores for Q2 FY26, which is a significant improvement of 77.84% compared to the previous quarter. Additionally, net sales grew by 10.23% quarter-on-quarter and 12.02% year-on-year, reaching ₹484.67 crores, indicating some positive momentum in revenue.<BR><BR>However, despite this growth in sales, the company remains in a loss-making position for the fifth consecutive quarter, raising concerns about its operational efficiency and business model sustainability. The operating margin has also declined to 9.12%, down from 11.26% a year ago, reflecting ongoing challenges in managing costs and maintaining profitability. Furthermore, the interest burden has increased significantly, which is consuming a large portion of the operating profits.<BR><BR>Overall, while there are signs of revenue growth, the persistent losses and declining margins suggest that the company is facing significant structural challenges. Therefore, the results can be viewed as concerning, indicating that while there are some positive developments, the overarching financial health of Indoco Remedies remains precarious.

How has been the historical performance of Indoco Remedies?

Indoco Remedies has experienced fluctuating financial performance, with net sales decreasing to 1,664.92 Cr in March 2025 from 1,817.29 Cr in March 2024, and a significant drop in operating profit leading to a profit before tax of -74.37 Cr. Despite an increase in total assets, the company faces challenges in profitability, as reflected by a profit after tax of -77.95 Cr in March 2025.

Answer:<BR>The historical performance of Indoco Remedies shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Indoco Remedies reported net sales of 1,664.92 Cr in March 2025, a decrease from 1,817.29 Cr in March 2024, but an increase from 1,668.61 Cr in March 2023. The total operating income followed a similar pattern, with a total of 1,664.92 Cr in March 2025 compared to 1,817.29 Cr in the previous year. The total expenditure, excluding depreciation, was 1,565.66 Cr in March 2025, slightly down from 1,572.98 Cr in March 2024. Operating profit (PBDIT) decreased significantly to 99.26 Cr in March 2025 from 244.31 Cr in March 2024, leading to a profit before tax of -74.37 Cr in March 2025, a stark contrast to the profit of 135.80 Cr in March 2024. Consequently, profit after tax also fell to -77.95 Cr in March 2025 from 97.01 Cr in the previous year. The company's total assets increased to 2,429.91 Cr in March 2025 from 2,144.73 Cr in March 2024, while total liabilities rose to 2,429.91 Cr from 2,144.73 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 94.00 Cr in March 2025 from 155.00 Cr in March 2024, and the closing cash and cash equivalents were reported at 12.00 Cr in March 2025, down from 14.00 Cr in March 2024. Overall, the financial performance of Indoco Remedies reflects challenges in profitability despite growth in sales and total assets.

Is Indoco Remedies technically bullish or bearish?

As of December 2, 2025, Indoco Remedies exhibits a neutral technical trend with mixed signals, showing a mildly bearish outlook on weekly indicators and a lack of clear direction overall.

As of 2 December 2025, the technical trend for Indoco Remedies has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are bearish, while the monthly MACD and KST are mildly bullish, indicating a lack of clear direction. The Bollinger Bands are mildly bearish on both weekly and monthly charts, reinforcing the sideways trend. Daily moving averages show a mildly bullish stance, but this is countered by the overall bearish signals from the weekly indicators. The Dow Theory indicates a mildly bearish outlook on the weekly timeframe, while the monthly shows no trend. Overall, the strength of the current neutral stance is weak, driven primarily by conflicting signals across various indicators.

Should I buy, sell or hold Indoco Remedies?

Which are the latest news on Indoco Remedies?

Which are the latest news on Indoco Remedies?

Why is Indoco Remedies falling/rising?

As of 22-Dec, Indoco Remedies Ltd's stock is at 237.40, down -1.31%, and has significantly underperformed the Sensex with a year-to-date decline of -28.60%. The company's financial health is poor, marked by a high Debt to EBITDA ratio and negative results for 12 consecutive quarters, leading to a negative outlook for the stock.

As of 22-Dec, Indoco Remedies Ltd's stock price is falling, currently at 237.40, reflecting a change of -3.15 (-1.31%). The stock has underperformed significantly against the benchmark Sensex, with a year-to-date decline of -28.60% compared to the Sensex's gain of +9.51%. Over the past year, the stock has also shown a substantial drop of -29.88%, while the Sensex increased by +9.64%. <BR><BR>The company's financial health is concerning, as indicated by a high Debt to EBITDA ratio of 4.18 times, which suggests a low ability to service debt. Additionally, the company has reported negative results for the last 12 consecutive quarters, with operating profit growth at an alarming annual rate of -185.53% over the last five years. This has contributed to a negative return on equity of 9.06%, indicating low profitability per unit of shareholders' funds.<BR><BR>Investor sentiment appears to be declining, as evidenced by a decrease in institutional investor participation, which has fallen by -0.77% over the previous quarter. This decline in institutional interest, combined with the stock's consistent underperformance against benchmarks over the last three years, further exacerbates the negative outlook for Indoco Remedies. Overall, these factors collectively contribute to the stock's downward trend.

Why is Indoco Remedies Ltd falling/rising?

As of 23-Dec, Indoco Remedies Ltd's stock price is at 237.75, showing a minor increase today but a significant decline over various periods, including a 28.50% drop year-to-date. The stock is underperforming against its moving averages and experiencing reduced investor participation, indicating a cautious outlook.

As of 23-Dec, Indoco Remedies Ltd's stock price is currently at 237.75, reflecting a slight increase of 0.45 (0.19%). Despite this minor rise today, the stock has shown a significant decline over various periods. Over the past week, it has decreased by 3.06%, and over the past month, it has fallen by 7.94%. Year-to-date, the stock is down 28.50%, and it has also dropped 28.02% over the past year. In a longer-term view, the stock has decreased by 37.30% over three years and 16.67% over five years, while the benchmark Sensex has experienced positive returns during these same periods.<BR><BR>Today's performance indicates that Indoco Remedies has outperformed its sector by 0.4%, but it is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a notable decline in investor participation, with the delivery volume on December 22 falling by 42.86% compared to the 5-day average. This suggests a decrease in trading activity and interest in the stock.<BR><BR>Overall, while there is a slight uptick in the stock price today, the broader trend indicates a significant decline in value over time, coupled with reduced investor participation, which may contribute to a cautious outlook for Indoco Remedies Ltd.

Why is Indoco Remedies Ltd falling/rising?

As of 24-Dec, Indoco Remedies Ltd's stock is at 234.00, down 1.18%, and has significantly underperformed against the Sensex, with a year-to-date decline of 29.62%. The company's financial health is concerning, marked by negative results for 12 quarters and a high Debt to EBITDA ratio, leading to reduced institutional investor confidence.

As of 24-Dec, Indoco Remedies Ltd's stock price is falling, currently at 234.00, reflecting a decrease of 2.8 (-1.18%). The stock has been underperforming significantly against the benchmark, with a 1-week decline of 2.44% compared to a 1.00% increase in the Sensex. Over the past month, the stock has dropped by 7.58%, while the Sensex has only increased by 0.60%. Year-to-date, the stock has plummeted by 29.62%, contrasting sharply with the Sensex's gain of 9.30%.<BR><BR>The stock has been on a downward trend, having fallen for three consecutive days, resulting in a total decline of 2.72% during this period. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent weakness in its price performance. Additionally, the company has reported negative results for the last 12 consecutive quarters, and its operating profit has decreased at an alarming annual rate of 185.53% over the past five years.<BR><BR>The financial health of Indoco Remedies Ltd raises concerns, as evidenced by a high Debt to EBITDA ratio of 4.18 times, indicating a low ability to service debt. The Return on Equity stands at a mere 9.06%, suggesting low profitability per unit of shareholders' funds. Furthermore, institutional investors have reduced their stake by 0.77% in the last quarter, reflecting a lack of confidence in the company's prospects.<BR><BR>Overall, the combination of consistent underperformance against benchmarks, deteriorating financial metrics, and negative investor sentiment contributes to the stock's decline.

Why is Indoco Remedies Ltd falling/rising?

As of 25-Dec, Indoco Remedies Ltd's stock price is falling, currently at 234.00, reflecting a decline of -1.18%. The stock has significantly underperformed the Sensex, with a year-to-date drop of -29.62% due to high debt levels, negative financial results, and reduced institutional confidence.

As of 25-Dec, Indoco Remedies Ltd's stock price is falling, currently at 234.00, reflecting a change of -2.8 (-1.18%). The stock has underperformed significantly compared to the benchmark Sensex, with a decline of -2.44% over the past week and -7.58% over the past month, while the Sensex has shown positive returns of +1.00% and +0.60%, respectively. Year-to-date, the stock has dropped by -29.62%, contrasting sharply with the Sensex's gain of +9.30%.<BR><BR>The stock's performance today indicates a consistent downward trend, as it has been losing for the last three days, accumulating a total decline of -2.72% during this period. Additionally, Indoco Remedies is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals weakness in price momentum.<BR><BR>Several negative factors contribute to this decline. The company has a high Debt to EBITDA ratio of 4.18 times, indicating a low ability to service its debt. Furthermore, it has reported negative results for the last 12 consecutive quarters, with an operating profit growth rate of -185.53% over the past five years. The Return on Equity (ROE) stands at a low average of 9.06%, reflecting poor profitability. Institutional investors have also reduced their stakes by -0.77% in the previous quarter, suggesting a lack of confidence in the company's prospects.<BR><BR>Overall, the combination of poor financial performance, high debt levels, and consistent underperformance against the benchmark has led to a decline in the stock price of Indoco Remedies Ltd.

Why is Indoco Remedies Ltd falling/rising?

As of 26-Dec, Indoco Remedies Ltd's stock price is at 227.30, reflecting a 2.99% decrease. The stock has been on a downward trend, losing 31.64% year-to-date, driven by poor financial performance, high debt levels, and negative investor sentiment.

As of 26-Dec, Indoco Remedies Ltd's stock price is falling, currently at 227.30, which reflects a decrease of 7.0 points or 2.99%. The stock has been on a downward trend, having lost 5.51% over the past week and 12.56% over the past month. This decline is part of a longer-term trend, with the stock down 31.64% year-to-date and 31.37% over the past year, significantly underperforming the Sensex, which has gained 8.83% in the same period.<BR><BR>The stock's performance today has underperformed its sector by 2.54%, and it has experienced a consecutive fall for the last four days. It reached an intraday low of Rs 225.15, marking a 3.91% drop. Furthermore, Indoco Remedies is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Several negative factors contribute to this decline. The company has a high Debt to EBITDA ratio of 4.18 times, indicating a low ability to service its debt. Additionally, it has reported negative results for the last 12 consecutive quarters, with operating profit declining at an alarming annual rate of 185.53% over the past five years. The Return on Equity is low at 9.06%, and profits have plummeted by 552.7% over the past year. Institutional investor participation has also decreased, with a 0.77% reduction in their stake, suggesting a lack of confidence in the company's prospects.<BR><BR>Overall, the combination of poor financial performance, high debt levels, and consistent underperformance against benchmarks has led to the stock's decline.